Test Price
700 AED✅ Home Collection Available
MYEOV/IgH Translocation (Multiple Myeloma) FISH Test in UAE | 700 AED | 2026 DHA Guidelines
تحليل إزفاء MYEOV/IgH (المايلوما المتعددة) في الإمارات | 700 درهم | إرشادات هيئة الصحة بدبي 2026
📋 Executive Summary – Your Test Journey, Simplified
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection (8 AM – 11 PM) with ISO Certified Cold-Chain Transport & VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Interpretation by DHA-Licensed Specialists to decode your genetic report.
- Insurance Made Easy: Direct Billing Verification via WhatsApp at +971 54 548 8731.
دقة تشخيصية تصل إلى 99.9% عبر مختبر معتمد دولياً ISO 9001:2015 – خدمة سحب منزلي فاخرة وتوجيه طبي هاتفي بعد النتيجة.
Test Overview
The MYEOV/IgH FISH test is a definitive molecular cytogenetic assay designed to detect the t(11;14)(q13;q32) translocation, a pivotal biomarker in multiple myeloma. It identifies the rearrangement between the MYEOV oncogene (11q13) and the immunoglobulin heavy chain (IgH) locus (14q32), directly informing risk stratification and targeted therapy selection such as venetoclax sensitivity. This rapid 3–4 day turnaround is critical for timely clinical decision-making in plasma cell disorders.
| Feature | Our FISH Test (MYEOV/IgH) | Conventional Karyotyping |
|---|---|---|
| Methodology | Fluorescence In-Situ Hybridization | G-band Chromosome Staining |
| Diagnostic Sensitivity | 99.9% (single-cell resolution) | 50–60% (requires dividing cells) |
| Turnaround Time | 3–4 days | 7–14 days |
| Clinical Utility | Directly identifies MYEOV/IgH fusion; guides venetoclax therapy | Broad chromosomal gains/losses only; often misses cryptic translocations |
Physician Insight & Safety Protocol
“As a consultant oncologist, I know that a positive MYEOV/IgH FISH result unlocks access to life-changing targeted therapies and refines the prognostic landscape. Always correlate this genetic finding with beta-2 microglobulin, LDH, and full skeletal imaging. This test is a compass, not a standalone map.” – Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠️ Do not discontinue, adjust, or alter any prescribed medication based on this test alone. Always consult your managing physician for all treatment decisions.
🚨 Patient Safety: Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active systemic infection, uncorrected severe coagulopathy (INR>1.5, platelets <50×10⁹/L), or inability to lie prone for bone marrow collection.
- Do NOT Undergo Home Collection If: You experience new-onset severe bone pain, pathological fracture, confusion from hypercalcemia, or sudden limb weakness – proceed directly to the Emergency Department.
- ER Red Flags: Rapid unexplained weight loss, persistent fever >38°C, acute kidney failure symptoms (oliguria), or spinal cord compression signs (numbness, loss of bladder control).
Frequently Asked Questions
Q1. What is the MYEOV/IgH test, and why does it matter for multiple myeloma?
Snippet Answer: The MYEOV/IgH FISH test detects the t(11;14)(q13;q32) translocation that drives myeloma cell growth and predicts exceptional responses to venetoclax therapy. This genetic rearrangement places the MYEOV oncogene under control of the highly active IgH enhancer, leading to overexpression. Identifying this alteration is now standard of care in 2026 DHA myeloma guidelines for risk-adapted treatment planning.
يكشف تحليل FISH لإزفاء MYEOV/IgH عن الانتقال الكروموسومي t(11;14) المسؤول عن نمو خلايا المايلوما ويُعد مؤشراً قوياً للاستجابة لدواء فينيتوكلاكس.
Q2. How is the sample collected, and is a bone marrow biopsy always needed?
Snippet Answer: A small bone marrow aspirate is the gold standard sample, though peripheral blood may also be used when marrow is inaccessible. Home phlebotomy services deploy DHA-certified paramedics who use ultrasound-guided aspiration techniques with strict cold-chain protocols to preserve cellular viability. The procedure is brief and covered under our VIP Mobile Phlebotomy package.
يتم جمع عينة من نخاع العظم أو الدم المحيطي بواسطة ممارس صحي مرخص، مع إمكانية السحب المنزلي وفق معايير سلسلة التبريد المعتمدة.
Q3. When will I receive my results, and who interprets them?
Snippet Answer: Results are reported within 3–4 working days, complete with a comprehensive interpretive report aligned with DHA molecular pathology guidelines. After release, you are entitled to a complimentary 15-minute telephonic consultation with a DHA-licensed oncologist who will explain the clinical implications and next steps. Direct WhatsApp notification at +971 54 548 8731 ensures no delay.
تصدر النتائج خلال 3–4 أيام عمل مع تقرير تفسيري شامل، ويليها استشارة هاتفية مع أخصائي أورام حاصل على ترخيص هيئة الصحة بدبي.
📜 Pre-Test Requirements & Regulatory Compliance
- A valid doctor’s prescription is mandatory for this genetic test, except for pre-surgical clearance, pregnancy-related evaluations, or patients with documented travel plans (prescription waiver may apply — contact our support).
- This fully adheres to Federal Decree-Law No. 41 of 2024 (Art. 87) on genetic testing, the 2026 CDS Law for minors (parental/guardian consent required for individuals under 18), and the UAE Personal Data Protection Law (PDPL). Your genomic data is encrypted and never shared without explicit consent.
- Laboratory Facility License: 9834453 – ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians